Study Objectives: Recently published guidelines advise limiting opioids prescriptions for acute painful episodes to a 3-day supply; however, there is little literature available to quantify patterns of opioid use after an ED visit. Additionally, the number of pills included in a 3-day supply is not quantified in guidelines and may vary widely (eg, a 3-day supply of hydrocodone-acetaminophen using typical dosing intervals could be 12 tabs (1 PO Q6 hours) or 36 tabs (2 PO Q4 hours)). We sought to describe opioid consumption patterns after an ED visit for acute pain and quantify the proportion of patients who would exceed a 3-day supply at the commonly dispensed quantity of 12 tabs.
Study Objectives: Recently published guidelines advise limiting opioids prescriptions for acute painful episodes to a 3-day supply; however, there is little literature available to quantify patterns of opioid use after an ED visit. Additionally, the number of pills included in a 3-day supply is not quantified in guidelines and may vary widely (eg, a 3-day supply of hydrocodone-acetaminophen using typical dosing intervals could be 12 tabs (1 PO Q6 hours) or 36 tabs (2 PO Q4 hours)). We sought to describe opioid consumption patterns after an ED visit for acute pain and quantify the proportion of patients who would exceed a 3-day supply at the commonly dispensed quantity of 12 tabs.
Methods: As part of a larger interventional study promoting the safe use of opioids after an ED visit to an urban academic hospital (>88,000 visits), patients completed a 10-day medication diary documenting their medication consumption (including both analgesics and other home medications). Patients were enrolled if they were age >17 years, received a prescription for hydrocodone-acetaminophen and did not chronically use opioids. Patients were included in this analysis if they returned the completed medication diary and had a discharge diagnosis in 1 of 4 categories: back pain, kidney stone, fracture or musculoskeletal injury (non-fracture). Patient demographics and pain scores are reported. Opioid consumption is described using daily number of pills consumed and daily morphine milligram equivalents (MMEs) both for the sample overall and by diagnosis group. Additionally the proportion of patients continuing opioid use is reported by post-visit-day both overall and by diagnosis.
Results: 191 patients with the diagnoses listed above returned completed medication diaries [45 (24%) back pain, 52 kidney stone (27%), 54 fracture (28%), 40 (21%) musculoskeletal injury (non fracture)]. Mean Age a 6 years (sd 14), 57% female. Pain scores on ED presentation were high and remained high post discharge (eg, Day 1: 7 (N¼161), Day 2: 7 (N¼143), Day 3: 6 (N¼122)). Mean quantity of opioid pills prescribed: 16 tabs. On the day of discharge (Day 1), 85% of patients consumed an opioid at home (87% back pain, 73% kidney stone, 93% fracture, 88% musculoskeletal injury) with a mean tabs consumed of 1.7 (sd 1), resulting in 11.2 (7.9) MME (13.9 (11.4) MME back pain, 9.5 (5.2) MME kidney stone, 10.7 (6.9) MME fracture, 11.1 (6.6) MME musculoskeletal injury). The proportion of patients consuming opioids on subsequent days decreased on the day after discharge for patients with kidney stones (42%) and fractures (81%), remained stable for those with musculoskeletal pain (90%) and increased for those with back pain (91%). Among those patients taking pills on the first 2 days after discharge (Day 2 and Day 3) the MME consumed increased (15 (10.2) and 15.6 (12.2) MME, respectively) before decreasing on subsequent days (Day 4: 13.5 (11.5) MME, Day 5 13.3 (9.2) MME). Only 7.7% of kidney stone patients consumed more than 12 pills; whereas 42.2% of back pain patients consumed more than 12 pills in the 10 days post-discharge. 81% of patients had leftover pills (66% back pain, 96% kidney stones, 74% fracture, 87% musculoskeletal injury).
Conclusions: In this sample, pill consumption varied by illness category; however, overall patients were consuming low quantities of pills and the majority had unused pills 10-days after their ED visit. Further data could help support prescribing tailored by diagnosis and minimize unused pills.
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Safety of Subcutaneous Opioid Administration at Triage for the Treatment of Sickle Cell Vaso-Occlusive Crises Freiermuth C, Perriello E, Mando J/University of Cincinnati, Cincinnati, OH; Duke University, Durham, NC Study Objectives: The National Heart Lung and Blood Institute published guidelines for the treatment of sickle cell disease in 2014. Within the section on management of acute complications, the recommendation was to administer parenteral opioids within 30 minutes of triage or 60 minutes of registration. Due to current crowding in emergency departments (ED), some patients remain in the waiting room for an extended amount of time. This study sought to determine if patients suffered any adverse events following receipt of subcutaneous opioids for treatment of vasoocclusive crisis while still in the waiting room.
Methods: This was a retrospective chart review performed at a single academic urban hospital. Patients were included if they were over the age of 18, had a chief complaint of sickle cell crisis and received a dose of subcutaneous opioid while in triage or the waiting room between July 1, 2013-June 30, 2016. Data was abstracted directly into a REDCap database by one of the investigators. Variables included demographic data, vital signs, times of arrival, bed assignment and disposition, pain scores, adverse events that occurred within 90 minutes, and any interventions associated with adverse events. Major adverse events were defined as administration of naloxone, CPR, intubation, respiratory depression (RR<10 breaths/min or O2 saturation <92%), hypotension (SBP<90 mmHg) or a Richmond Agitation Sedation Scale (RASS) of <1. Minor adverse events included nausea, vomiting, pruritis, dizziness, somnolence or fatigue. Adverse events are reported as a count and percentage, with inclusion of descriptive details.
Results: Initial query of the pharmacy database identified 289 encounters that involved an order for subcutaneous opioids for a patient in the ED waiting room. 187 encounters were excluded, most commonly because the patient did not have sickle cell disease. Of the remaining 102 encounters, no patients received naloxone, required CPR or intubation or had documented hypotension or depressed RASS. Three patients experienced respiratory depression. One of these had an initial saturation of 92%, which dropped to 90% after a dose of opioid. He was placed on 2L O2 with good response. Two other patients had a documented drop in their oxygen saturation levels after administration of a second dose of subcutaneous opioid. One fell from 100% to 91%, but improved without intervention. The other fell from 98% to 88%, was placed on 2L O2 with good response and was ultimately discharged. The only minor adverse events that were documented was nausea, affecting 3 patients (2.9%).
Conclusions: Adverse events following administration of subcutaneous opioids for the treatment of sickle cell vaso-occlusive crises are rare. Multiple doses of opioids increases the risk of adverse events in this patient population.
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Analyzing the Impact of Low-Acuity Emergency Medical Services Arrivals on Resource Utilization in the Emergency Department Lombardi KM, Yiu A, Pourmand A/George Washington University, Washington, DC Study Objectives: The use of emergency medical services (EMS) transport for lowacuity patient visits utilizes resources which are better suited for higher-acuity conditions and contributes to increased emergency department (ED) expenses and crowding. In this study we sought to elucidate the characteristics of low-acuity EMS arrivals and contrast them with other patient populations by both method of arrival and patient acuity.
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